JASON KIMATA to Recombinant Proteins
This is a "connection" page, showing publications JASON KIMATA has written about Recombinant Proteins.
Connection Strength
0.217
-
ICAM-3 influences human immunodeficiency virus type 1 replication in CD4(+) T cells independent of DC-SIGN-mediated transmission. Virology. 2007 Aug 01; 364(2):383-94.
Score: 0.055
-
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
Score: 0.041
-
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
Score: 0.039
-
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
Score: 0.038
-
The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. J Virol. 2016 Dec 01; 90(23):10642-10659.
Score: 0.027
-
Temporal regulation of viral and cellular gene expression during human T-lymphotropic virus type I-mediated lymphocyte immortalization. J Virol. 1991 Aug; 65(8):4398-407.
Score: 0.018